en · de · es · fr · pt
aod-9604-notes.peptides6908.com › Guide › Identity And Research Origin — Explained

Identity And Research Origin — Explained

By Editorial Desk · published 2025-08-09 · last reviewed 2025-09-24 · Guide

The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-09-24. Anything still debated is marked as such rather than presented as settled.

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Research and Regulatory Context

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Related pages on this site

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Identity And Research Background

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

Notes from published material

== External links == R&D - Protagenic Therapeutics Breakthrough Therapeutics for Stress-Related Neuropsychiatric Disorders (Corporate Overview, August 2021) - Protagenic Therapeutics US SEC FORM 10-K - Protagenic Therapeutics, Inc. (discusses PT00114)

==== Immune regulation ==== Under glutamine-deprived conditions, α-ketoglutarate promotes naïve CD4+ T cells differentiation into inflammation-promoting Th1 cells while inhibiting their differentiation into inflammation-inhibiting Treg cells thereby promoting certain inflammation responses.

1993/3045) Broadcasting (Prescribed Countries) (Amendment) Order 1993 (S.I. 1993/3046) Broadcasting (Foreign Satellite Programmes) (Specified Countries) (Amendment) Order 1993 (S.I. 1993/3047) Road Vehicles (Construction and Use) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3048) Public Lending Right Scheme 1982 (Commencement of Variation) Order 1993 (S.I. 1993/3049) Notification of New Substances Regulations 1993 (S.I. 1993/3050) Hearing Aid Council Monetary Penalty (Increase) Order 1993 (S.I. 1993/3052) Commercial Agents (Council Directive) Regulations 1993 (S.I. 1993/3053) Local Authorities (Capital Finance) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3054) Income Tax (Interest Relief) (Qualifying Lenders) (No. 4) Order 1993 (S.I. 1993/3055) Education (University Commissioners) Order 1993 (S.I. 1993/3056) National Health Service Trusts (Consultation on Dissolution) (Scotland) Regulations 1993 (S.I. 1993/3057) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) (Partial Revocation No.2) Order 1993 (S.I. 1993/3058) Non-Domestic Rating Contributions (Scotland) Amendment Regulations 1993 (S.I. 1993/3059) New Town (Livingston) Winding Up Order 1993 (S.I. 1993/3060) New Town (Irvine) Winding Up Order 1993 (S.I. 1993/3061) New Town (Cumbernauld) Winding Up Order 1993 (S.I. 1993/3062) Herring (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3063) Passenger and Goods Vehicles (Recording Equipment) (Approval of Fitters and Workshops) (Fees) (Amendment) Regulations 1993 (S.I.

1/2 S8 + H2O + 2 Ca(OH)2 → 2 H2S + CaS2O3 3/8 S8 + H2O + 2 Ca(OH)2 → 2 H2S + CaSO3 1/2 S8 + 2 H2O + 2 Ca(OH)2 → 3 H2S + CaSO4 However, elemental sulfur can undergo a disproportionation reaction, also called dismutation. The first reaction resembles a disproportionation reaction. The inverse comproportionation reaction occurs in the Claus process, which is used for desulfurization of oil and gas products in the refining industry:

These included French pharmacist Alexandre Rouhier's Le Peyotl: La Plante Qui Fait les Yeux Émerveillés (Peyote: The Plant That Fills the Eyes with Marvels) in 1927, the German psychiatrist Kurt Beringer's Der Meskalinrausch, seine Geschichte und Erscheinungsweise (Mescaline Intoxication, its History and Manifestation) in 1927, and German–American psychologist Heinrich Klüver's Mescal: The Divine Plant and Its Psychological Effects in 1928. Studies of the potential therapeutic effects of mescaline started in the 1950s. It was studied as part of psychedelic-assisted psychotherapy by Walter Frederking by 1953. Aldous Huxley's book The Doors of Perception, about his experience with mescaline, was published in 1954. In 1955, English politician Christopher Mayhew took part in an experiment for BBC's Panorama, in which he ingested 400 mg of mescaline under the supervision of psychiatrist Humphry Osmond. Though the recording was deemed too controversial and ultimately omitted from the show, Mayhew praised the experience, calling it "the most interesting thing I ever did" and saying that it was "profoundly thought-provoking". The mechanism of action of mescaline, activation of the serotonin 5-HT2A receptors, became fully known in the 1990s. A serotonin 5-HT2A receptor antagonist, specifically ketanserin, was first clearly shown to block the psychedelic effects of mescaline in humans by Matthias Liechti and colleagues in 2024. The history of mescaline was reviewed in the 2019 book Mescaline: A Global History of the First Psychedelic by cultural historian Mike Jay.

Sources: en.wikipedia.org

Further detail

=== Metallocenium ions === The most famous example is ferrocenium, [Fe(C5H5)2]+, the blue iron(III) complex derived from oxidation of orange iron(II) ferrocene. The lithocene anion, [Li(C5H5)2]–, is the best-documented example of a metallocene anion; otherwise such ions are little known.

=== Other uses === Chlorpromazine is occasionally used off-label for treatment of severe migraine. It is often, particularly as palliation, used in small doses to reduce nausea by opioid-treated cancer patients and to intensify and prolong the analgesia of the opioids as well. Efficacy has been shown in treatment of symptomatic hypertensive emergency. In Germany, chlorpromazine still carries label indications for insomnia, severe pruritus, and preanesthesia. Chlorpromazine has been used as a hallucinogen antidote or "trip killer" to block the effects of serotonergic psychedelics like psilocybin, lysergic acid diethylamide (LSD), and mescaline. However, it was said to not be completely effective and could exacerbate symptoms under certain situations. The results of clinical studies of chlorpromazine for this use have been inconsistent, with reduced effects, no change in effects, and even enhanced effects all reported. Intravenous chlorpromazine is described as completely abolishing the autonomic and psychoactive effects of LSD, whereas oral chlorpromazine is said to be much less effective. Chlorpromazine and other phenothiazines have been demonstrated to possess antimicrobial properties, but are not currently used for this purpose except for a very small number of cases. For example, Miki et al. 1992 trialed daily doses of chlorpromazine, reversing chloroquine resistance in Plasmodium chabaudi isolates in mice. Weeks et al., 2018 find that it also possesses a wide spectrum anthelmintic effect. Chlorpromazine is an antagonist of several insect monoamine receptors.

12 October Researchers report successful transplantation of human brain tissue organoids into baby rats. Such research could eventually controversially raise ethical issues relating to (non-)human intelligence/consciousness/welfare and be used to model human brain development and, as demonstrated, to investigate diseases (and their potential therapies). Unlike in other recent studies, the tissues appeared to be highly functional, to mature and to integrate with the rat brain. A study reports that in a cohort of symptomatically infected, 46% had only partially recovered after 12 months, that asymptomatic infection was not associated with adverse outcomes of long COVID and that vaccination was associated with reduced risk of seven long-term symptoms. A meta-analysis published on the same day reports substantial exercise intolerance more than 3 months after infection in long COVID-19 patients. It notes that post-exertional malaise has been reported in long COVID-19 similar to CFS. 13 October A novel synthetic biology-based process for recycling of plastics mixtures is presented. Scientists report that in some cases, some apparently senescent cells – which are targeted by anti-aging senolytics – are required for regeneration. 14 October – Scientists from Boston University publish unauthorized (but legal) research on SARS-CoV-2 BA.1 Omicron via creation of a highly transmissible recombinant virus as a preprint, described by "many" but not all as "irresponsible gain-of-function" research.

=== Biology === C4, an EEG electrode site according to the 10-20 system Apolipoprotein C4, a protein encoded by the APOC4 gene c4 antisense RNA, a non-coding RNA ATC code C04 Peripheral vasodilators, a subgroup of the Anatomical Therapeutic Chemical Classification System C4 carbon fixation, a pathway for carbon fixation in photosynthesis that produces C4 plants Cervical spinal nerve 4, a nerve originating in the neck Cervical vertebra 4, one of the cervical vertebrae of the vertebral column C04, oral cancer ICD-10 code Complement component 4, a protein involved in the intricate complement system, encoded by C4A or C4B gene in humans C4 fragments, one of the types of products of catabolism pathways

Photoacoustic Tomography (PAT) is a hybrid imaging modality that utilizes the photoacoustic effect without the use of ionizing radiation. It works without contact with very fast laser pulses that generate ultrasound in the tissue under examination. The local absorption of the light leads to sudden local heating and the resulting thermal expansion. The result is broadband acoustic waves. The original distribution of absorbed energy can be reconstructed by measuring the outgoing ultrasound waves with appropriate ultrasound transducers.

Sources: en.wikipedia.org

Background from the literature

=== Single gene disorders === Autosomal dominant and recessive single gene disorders which have been diagnosed prenatally by analysing paternally inherited DNA include cystic fibrosis, beta thalassemia, sickle cell anemia, spinal muscular atrophy, and myotonic dystrophy. Prenatal diagnosis of single gene disorders which are due to an autosomal recessive mutation, a maternally inherited autosomal dominant mutation or large sequence mutations that include duplication, expansion or insertion of DNA sequences is more difficult. In cffDNA, fragments of 200 – 300 bp length involved in single gene disorders are more difficult to detect. For example, the autosomal dominant condition, achondroplasia is caused by the FGFR3 gene point mutation. In two pregnancies with a fetus with achondroplasia was found a paternally inherited G1138A mutation from cffDNA from a maternal plasma sample in one and a G1138A de novo mutation from the other. In studies of the genetics of Huntington's chorea using qRT-PCR of cffDNA from maternal plasma samples, CAG repeats have been detected at normal levels (17, 20 and 24). cffDNA may also be used to diagnose single gene disorders. Developments in laboratory processes using cffDNA may allow prenatal diagnosis of aneuploidies such as trisomy 21 (Down syndrome) in the fetus.

=== Major players === In terms of companies engaging directly in logistics, the sector in SA is highly competitive, with no dominant players. Among companies operating in the market are SA-based Transnet, UAE-based DP World (including its SA subsidiary Imperial Logistics), Switzerland-based Kuehne+Nagel, German-based DHL Group, and Denmark-based DSV (including German subsidiary DB Schenker).

Seth helps a very drunk Amber through her breakup with her fiancé, Ryan. It is shown that Seth is finally able to support himself with a job and house. He and Sarah chat later on about how he's doing over the phone. Seth sends Amber a baby crib to assemble once he discovers that she is pregnant.

=== Honey bee products === Honey bee products are used medicinally across Asia, Europe, Africa, Australia, and the Americas, despite the fact that the honey bee was not introduced to the Americas until the colonization by Spain and Portugal. They are by far the most common medical insect product, both historically and currently. Honey is the most frequently referenced medical bee material. It can be applied to skin to treat excessive scar tissue, rashes, and burns, and can be applied as a poultice to eyes to treat infection. It is also consumed for digestive problems and as a general health restorative, and can be heated and consumed to treat head colds, cough, throat infections, laryngitis, tuberculosis, and lung diseases. Additionally, apitoxin, or honey bee venom, can be applied via direct stings to relieve arthritis, rheumatism, polyneuritis, and asthma. Propolis, a resinous, waxy mixture collected by honeybees and used as a hive insulator and sealant, is often consumed by menopausal women because of its high hormone content, and it is said to have antibiotic, anesthetic, and anti-inflammatory properties. Royal jelly is used to treat anemia, gastrointestinal ulcers, arteriosclerosis, hypo- and hypertension, and inhibition of sexual libido. Finally Bee bread, or bee pollen, is eaten as a generally health restorative, and is said to help treat both internal and external infections. All of these honey bee products are regularly produced and sold, especially online and in health food stores, though none are yet approved by the FDA.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Network